Study Provides Path for New Immunotherapy Approaches to Prostate Cancer

FDA Approves Hep C Drugs for Kids 12 and Older
April 20, 2017
Psoriasis, often misdiagnosed, may lead to heart disease and other serious ailments
April 20, 2017
Show all

Study Provides Path for New Immunotherapy Approaches to Prostate Cancer

Immunotherapy is being researched to fight prostate cancer.

Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

Based on their findings, the researchers launched a clinical trial for stage IV prostate cancer in March combining two drugs that target separate brakes on the immune system. The checkpoint inhibitors largely failed individually against the disease. Their results also implicate for the first time on a human tumor a third brake called VISTA in potentially inhibiting immune response.

“We’ve known that prostate cancer is immunologically cold, or quiet, with very little penetration of the tumors or their surrounding microenvironment by immune cells,” said study leader Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology.

“Our study explored whether we could increase immune cell infiltration by combining the anti-hormonal drug Lupron with two rounds of the checkpoint inhibitor ipilimumab before surgery in patients with locally advanced prostate cancer,” Sharma said.

Read full article: Study Provides Path for New Immunotherapy Approaches to Prostate Cancer

Read Full Article: Study Provides Path for New Immunotherapy Approaches to Prostate Cancer

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.